229 related articles for article (PubMed ID: 31353876)
21. Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer.
Msaouel P; Galeas JN; Boiles AR; Ruiz RR; Koutsilieris M
Curr Drug Targets; 2016; 17(3):276-89. PubMed ID: 25892311
[TBL] [Abstract][Full Text] [Related]
22. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
23. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
24. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
25. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
26. Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.
Southcott D; Awan A; Ghate K; Clemons M; Fernandes R
Curr Oncol; 2020 Aug; 27(4):220-224. PubMed ID: 32905286
[TBL] [Abstract][Full Text] [Related]
27. Radium 223 dichloride for prostate cancer treatment.
Deshayes E; Roumiguie M; Thibault C; Beuzeboc P; Cachin F; Hennequin C; Huglo D; Rozet F; Kassab-Chahmi D; Rebillard X; Houédé N
Drug Des Devel Ther; 2017; 11():2643-2651. PubMed ID: 28919714
[TBL] [Abstract][Full Text] [Related]
28. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
29. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
30. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
[TBL] [Abstract][Full Text] [Related]
31. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
32. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
33. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
34. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
Den RB; George D; Pieczonka C; McNamara M
Am J Clin Oncol; 2019 Apr; 42(4):399-406. PubMed ID: 30844849
[TBL] [Abstract][Full Text] [Related]
35. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
36. Nonhormone therapy for metastatic castration-resistant prostate cancer: chemotherapy, bone-targeted treatments, and others.
Fizazi K
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714488
[TBL] [Abstract][Full Text] [Related]
37. The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use.
Uemura H; DiBonaventura M; Wang E; Ledesma DA; Concialdi K; Aitoku Y
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):511-517. PubMed ID: 28277852
[TBL] [Abstract][Full Text] [Related]
38. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
39. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
40. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Dorff TB; Gross ME
Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]